Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial
Identifieur interne : 000193 ( Pmc/Corpus ); précédent : 000192; suivant : 000194Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial
Auteurs : Bruno Coudert ; Bernard Asselain ; Mario Campone ; Marc Spielmann ; Jean-Pascal Machiels ; Frédérique Pénault-Llorca ; Daniel Serin ; Christelle Lévy ; Gilles Romieu ; Jean-Luc Canon ; Hubert Orfeuvre ; Gilles Piot ; Thierry Petit ; Guy Jerusalem ; Bruno Audhuy ; Corinne Veyret ; Marc Beauduin ; Jean-Christophe Eymard ; Anne-Laure Martin ; Henri RochéSource :
- The Oncologist [ 1083-7159 ] ; 2012.
Abstract
The initial report from the PACS01 trial demonstrated a benefit at 5 years for disease-free survival and overall survival rates with the sequential administration of docetaxel after fluorouracil, epirubicin, and cyclophosphamide for patients with node-positive, operable breast cancer. This article evaluates the impact of this regimen at 8 years.
Url:
DOI: 10.1634/theoncologist.2011-0442
PubMed: 22610153
PubMed Central: 3399644
Links to Exploration step
PMC:3399644Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial</title><author><name sortKey="Coudert, Bruno" sort="Coudert, Bruno" uniqKey="Coudert B" first="Bruno" last="Coudert">Bruno Coudert</name><affiliation><nlm:aff id="aff1">Medical Oncology, Centre Georges-François Leclerc, Dijon, France;</nlm:aff></affiliation></author><author><name sortKey="Asselain, Bernard" sort="Asselain, Bernard" uniqKey="Asselain B" first="Bernard" last="Asselain">Bernard Asselain</name><affiliation><nlm:aff id="aff2">Statistical Department, Institut Curie, Paris, France;</nlm:aff></affiliation></author><author><name sortKey="Campone, Mario" sort="Campone, Mario" uniqKey="Campone M" first="Mario" last="Campone">Mario Campone</name><affiliation><nlm:aff id="aff3">Medical Oncology, Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Nantes, France;</nlm:aff></affiliation></author><author><name sortKey="Spielmann, Marc" sort="Spielmann, Marc" uniqKey="Spielmann M" first="Marc" last="Spielmann">Marc Spielmann</name><affiliation><nlm:aff id="aff4">Medical Oncology, Institut Gustave Roussy, Villejuif, France;</nlm:aff></affiliation></author><author><name sortKey="Machiels, Jean Pascal" sort="Machiels, Jean Pascal" uniqKey="Machiels J" first="Jean-Pascal" last="Machiels">Jean-Pascal Machiels</name><affiliation><nlm:aff id="aff5">Medical Oncology, Cliniques Universitaires Saint Luc, Bruxelles, Belgium;</nlm:aff></affiliation></author><author><name sortKey="Penault Llorca, Frederique" sort="Penault Llorca, Frederique" uniqKey="Penault Llorca F" first="Frédérique" last="Pénault-Llorca">Frédérique Pénault-Llorca</name><affiliation><nlm:aff id="aff6">Pathology Department, Centre Jean Perrin, Clermont-Ferrand, France;</nlm:aff></affiliation></author><author><name sortKey="Serin, Daniel" sort="Serin, Daniel" uniqKey="Serin D" first="Daniel" last="Serin">Daniel Serin</name><affiliation><nlm:aff id="aff7">Medical Oncology, Institut Sainte-Catherine, Avignon, France;</nlm:aff></affiliation></author><author><name sortKey="Levy, Christelle" sort="Levy, Christelle" uniqKey="Levy C" first="Christelle" last="Lévy">Christelle Lévy</name><affiliation><nlm:aff id="aff8">Medical Oncology, Centre François Baclesse, Caen, France;</nlm:aff></affiliation></author><author><name sortKey="Romieu, Gilles" sort="Romieu, Gilles" uniqKey="Romieu G" first="Gilles" last="Romieu">Gilles Romieu</name><affiliation><nlm:aff id="aff9">Medical Oncology, Centre Val d'Aurelle, Montpellier, France;</nlm:aff></affiliation></author><author><name sortKey="Canon, Jean Luc" sort="Canon, Jean Luc" uniqKey="Canon J" first="Jean-Luc" last="Canon">Jean-Luc Canon</name><affiliation><nlm:aff id="aff10">Medical Oncology, Grand Hôpital Charleroi, Charleroi, Belgium;</nlm:aff></affiliation></author><author><name sortKey="Orfeuvre, Hubert" sort="Orfeuvre, Hubert" uniqKey="Orfeuvre H" first="Hubert" last="Orfeuvre">Hubert Orfeuvre</name><affiliation><nlm:aff id="aff11">Medical Oncology, Centre Hospitalier Fleyriat, Bourg-en-Bresse, France;</nlm:aff></affiliation></author><author><name sortKey="Piot, Gilles" sort="Piot, Gilles" uniqKey="Piot G" first="Gilles" last="Piot">Gilles Piot</name><affiliation><nlm:aff id="aff12">Medical Oncology, Centre Medico-Chirurgical les Ormeaux, Le Havre, France;</nlm:aff></affiliation></author><author><name sortKey="Petit, Thierry" sort="Petit, Thierry" uniqKey="Petit T" first="Thierry" last="Petit">Thierry Petit</name><affiliation><nlm:aff id="aff13">Medical Oncology, Centre Paul Strauss, Strasbourg, France;</nlm:aff></affiliation></author><author><name sortKey="Jerusalem, Guy" sort="Jerusalem, Guy" uniqKey="Jerusalem G" first="Guy" last="Jerusalem">Guy Jerusalem</name><affiliation><nlm:aff id="aff14">Medical Oncology, Centre Hospitalo-Universitaire Sart-Tilman, Liège, Belgium;</nlm:aff></affiliation></author><author><name sortKey="Audhuy, Bruno" sort="Audhuy, Bruno" uniqKey="Audhuy B" first="Bruno" last="Audhuy">Bruno Audhuy</name><affiliation><nlm:aff id="aff15">Medical Oncology, Centre Hospitalier, Colmar, France;</nlm:aff></affiliation></author><author><name sortKey="Veyret, Corinne" sort="Veyret, Corinne" uniqKey="Veyret C" first="Corinne" last="Veyret">Corinne Veyret</name><affiliation><nlm:aff id="aff16">Medical Oncology, Centre Henri Becquerel, Rouen, France;</nlm:aff></affiliation></author><author><name sortKey="Beauduin, Marc" sort="Beauduin, Marc" uniqKey="Beauduin M" first="Marc" last="Beauduin">Marc Beauduin</name><affiliation><nlm:aff id="aff17">Medical Oncology, Hôpital Jolimont, Haine-Saint-Paul, Belgium;</nlm:aff></affiliation></author><author><name sortKey="Eymard, Jean Christophe" sort="Eymard, Jean Christophe" uniqKey="Eymard J" first="Jean-Christophe" last="Eymard">Jean-Christophe Eymard</name><affiliation><nlm:aff id="aff18">Medical Oncology, Institut Jean Godinot, Reims, France;</nlm:aff></affiliation></author><author><name sortKey="Martin, Anne Laure" sort="Martin, Anne Laure" uniqKey="Martin A" first="Anne-Laure" last="Martin">Anne-Laure Martin</name><affiliation><nlm:aff id="aff19">Unicancer, Fédération Nationale des Centres de Lutte Contre le Cancer, Paris, France;</nlm:aff></affiliation></author><author><name sortKey="Roche, Henri" sort="Roche, Henri" uniqKey="Roche H" first="Henri" last="Roché">Henri Roché</name><affiliation><nlm:aff id="aff20">Medical Oncology, Institut Claudius Regaud, Toulouse, France</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22610153</idno><idno type="pmc">3399644</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399644</idno><idno type="RBID">PMC:3399644</idno><idno type="doi">10.1634/theoncologist.2011-0442</idno><date when="2012">2012</date><idno type="wicri:Area/Pmc/Corpus">000193</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial</title><author><name sortKey="Coudert, Bruno" sort="Coudert, Bruno" uniqKey="Coudert B" first="Bruno" last="Coudert">Bruno Coudert</name><affiliation><nlm:aff id="aff1">Medical Oncology, Centre Georges-François Leclerc, Dijon, France;</nlm:aff></affiliation></author><author><name sortKey="Asselain, Bernard" sort="Asselain, Bernard" uniqKey="Asselain B" first="Bernard" last="Asselain">Bernard Asselain</name><affiliation><nlm:aff id="aff2">Statistical Department, Institut Curie, Paris, France;</nlm:aff></affiliation></author><author><name sortKey="Campone, Mario" sort="Campone, Mario" uniqKey="Campone M" first="Mario" last="Campone">Mario Campone</name><affiliation><nlm:aff id="aff3">Medical Oncology, Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Nantes, France;</nlm:aff></affiliation></author><author><name sortKey="Spielmann, Marc" sort="Spielmann, Marc" uniqKey="Spielmann M" first="Marc" last="Spielmann">Marc Spielmann</name><affiliation><nlm:aff id="aff4">Medical Oncology, Institut Gustave Roussy, Villejuif, France;</nlm:aff></affiliation></author><author><name sortKey="Machiels, Jean Pascal" sort="Machiels, Jean Pascal" uniqKey="Machiels J" first="Jean-Pascal" last="Machiels">Jean-Pascal Machiels</name><affiliation><nlm:aff id="aff5">Medical Oncology, Cliniques Universitaires Saint Luc, Bruxelles, Belgium;</nlm:aff></affiliation></author><author><name sortKey="Penault Llorca, Frederique" sort="Penault Llorca, Frederique" uniqKey="Penault Llorca F" first="Frédérique" last="Pénault-Llorca">Frédérique Pénault-Llorca</name><affiliation><nlm:aff id="aff6">Pathology Department, Centre Jean Perrin, Clermont-Ferrand, France;</nlm:aff></affiliation></author><author><name sortKey="Serin, Daniel" sort="Serin, Daniel" uniqKey="Serin D" first="Daniel" last="Serin">Daniel Serin</name><affiliation><nlm:aff id="aff7">Medical Oncology, Institut Sainte-Catherine, Avignon, France;</nlm:aff></affiliation></author><author><name sortKey="Levy, Christelle" sort="Levy, Christelle" uniqKey="Levy C" first="Christelle" last="Lévy">Christelle Lévy</name><affiliation><nlm:aff id="aff8">Medical Oncology, Centre François Baclesse, Caen, France;</nlm:aff></affiliation></author><author><name sortKey="Romieu, Gilles" sort="Romieu, Gilles" uniqKey="Romieu G" first="Gilles" last="Romieu">Gilles Romieu</name><affiliation><nlm:aff id="aff9">Medical Oncology, Centre Val d'Aurelle, Montpellier, France;</nlm:aff></affiliation></author><author><name sortKey="Canon, Jean Luc" sort="Canon, Jean Luc" uniqKey="Canon J" first="Jean-Luc" last="Canon">Jean-Luc Canon</name><affiliation><nlm:aff id="aff10">Medical Oncology, Grand Hôpital Charleroi, Charleroi, Belgium;</nlm:aff></affiliation></author><author><name sortKey="Orfeuvre, Hubert" sort="Orfeuvre, Hubert" uniqKey="Orfeuvre H" first="Hubert" last="Orfeuvre">Hubert Orfeuvre</name><affiliation><nlm:aff id="aff11">Medical Oncology, Centre Hospitalier Fleyriat, Bourg-en-Bresse, France;</nlm:aff></affiliation></author><author><name sortKey="Piot, Gilles" sort="Piot, Gilles" uniqKey="Piot G" first="Gilles" last="Piot">Gilles Piot</name><affiliation><nlm:aff id="aff12">Medical Oncology, Centre Medico-Chirurgical les Ormeaux, Le Havre, France;</nlm:aff></affiliation></author><author><name sortKey="Petit, Thierry" sort="Petit, Thierry" uniqKey="Petit T" first="Thierry" last="Petit">Thierry Petit</name><affiliation><nlm:aff id="aff13">Medical Oncology, Centre Paul Strauss, Strasbourg, France;</nlm:aff></affiliation></author><author><name sortKey="Jerusalem, Guy" sort="Jerusalem, Guy" uniqKey="Jerusalem G" first="Guy" last="Jerusalem">Guy Jerusalem</name><affiliation><nlm:aff id="aff14">Medical Oncology, Centre Hospitalo-Universitaire Sart-Tilman, Liège, Belgium;</nlm:aff></affiliation></author><author><name sortKey="Audhuy, Bruno" sort="Audhuy, Bruno" uniqKey="Audhuy B" first="Bruno" last="Audhuy">Bruno Audhuy</name><affiliation><nlm:aff id="aff15">Medical Oncology, Centre Hospitalier, Colmar, France;</nlm:aff></affiliation></author><author><name sortKey="Veyret, Corinne" sort="Veyret, Corinne" uniqKey="Veyret C" first="Corinne" last="Veyret">Corinne Veyret</name><affiliation><nlm:aff id="aff16">Medical Oncology, Centre Henri Becquerel, Rouen, France;</nlm:aff></affiliation></author><author><name sortKey="Beauduin, Marc" sort="Beauduin, Marc" uniqKey="Beauduin M" first="Marc" last="Beauduin">Marc Beauduin</name><affiliation><nlm:aff id="aff17">Medical Oncology, Hôpital Jolimont, Haine-Saint-Paul, Belgium;</nlm:aff></affiliation></author><author><name sortKey="Eymard, Jean Christophe" sort="Eymard, Jean Christophe" uniqKey="Eymard J" first="Jean-Christophe" last="Eymard">Jean-Christophe Eymard</name><affiliation><nlm:aff id="aff18">Medical Oncology, Institut Jean Godinot, Reims, France;</nlm:aff></affiliation></author><author><name sortKey="Martin, Anne Laure" sort="Martin, Anne Laure" uniqKey="Martin A" first="Anne-Laure" last="Martin">Anne-Laure Martin</name><affiliation><nlm:aff id="aff19">Unicancer, Fédération Nationale des Centres de Lutte Contre le Cancer, Paris, France;</nlm:aff></affiliation></author><author><name sortKey="Roche, Henri" sort="Roche, Henri" uniqKey="Roche H" first="Henri" last="Roché">Henri Roché</name><affiliation><nlm:aff id="aff20">Medical Oncology, Institut Claudius Regaud, Toulouse, France</nlm:aff></affiliation></author></analytic><series><title level="j">The Oncologist</title><idno type="ISSN">1083-7159</idno><idno type="eISSN">1549-490X</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>The initial report from the PACS01 trial demonstrated a benefit at 5 years for disease-free survival and overall survival rates with the sequential administration of docetaxel after fluorouracil, epirubicin, and cyclophosphamide for patients with node-positive, operable breast cancer. This article evaluates the impact of this regimen at 8 years.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Oncologist</journal-id><journal-id journal-id-type="iso-abbrev">Oncologist</journal-id><journal-id journal-id-type="pmc">oncologist</journal-id><journal-id journal-id-type="hwp">theoncologist</journal-id><journal-id journal-id-type="publisher-id">The Oncologist</journal-id><journal-title-group><journal-title>The Oncologist</journal-title></journal-title-group><issn pub-type="ppub">1083-7159</issn><issn pub-type="epub">1549-490X</issn><publisher><publisher-name>AlphaMed Press</publisher-name><publisher-loc>Durham, NC, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22610153</article-id><article-id pub-id-type="pmc">3399644</article-id><article-id pub-id-type="publisher-id">3780836</article-id><article-id pub-id-type="doi">10.1634/theoncologist.2011-0442</article-id><article-categories><subj-group subj-group-type="heading"><subject>Breast Cancer</subject></subj-group></article-categories><title-group><article-title>Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Coudert</surname><given-names>Bruno</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Asselain</surname><given-names>Bernard</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Campone</surname><given-names>Mario</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Spielmann</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Machiels</surname><given-names>Jean-Pascal</given-names></name><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pénault-Llorca</surname><given-names>Frédérique</given-names></name><xref ref-type="aff" rid="aff6"><sup>f</sup></xref></contrib><contrib contrib-type="author"><name><surname>Serin</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff7"><sup>g</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lévy</surname><given-names>Christelle</given-names></name><xref ref-type="aff" rid="aff8"><sup>h</sup></xref></contrib><contrib contrib-type="author"><name><surname>Romieu</surname><given-names>Gilles</given-names></name><xref ref-type="aff" rid="aff9"><sup>i</sup></xref></contrib><contrib contrib-type="author"><name><surname>Canon</surname><given-names>Jean-Luc</given-names></name><xref ref-type="aff" rid="aff10"><sup>j</sup></xref></contrib><contrib contrib-type="author"><name><surname>Orfeuvre</surname><given-names>Hubert</given-names></name><xref ref-type="aff" rid="aff11"><sup>k</sup></xref></contrib><contrib contrib-type="author"><name><surname>Piot</surname><given-names>Gilles</given-names></name><xref ref-type="aff" rid="aff12"><sup>l</sup></xref></contrib><contrib contrib-type="author"><name><surname>Petit</surname><given-names>Thierry</given-names></name><xref ref-type="aff" rid="aff13"><sup>m</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jerusalem</surname><given-names>Guy</given-names></name><xref ref-type="aff" rid="aff14"><sup>n</sup></xref></contrib><contrib contrib-type="author"><name><surname>Audhuy</surname><given-names>Bruno</given-names></name><xref ref-type="aff" rid="aff15"><sup>o</sup></xref></contrib><contrib contrib-type="author"><name><surname>Veyret</surname><given-names>Corinne</given-names></name><xref ref-type="aff" rid="aff16"><sup>p</sup></xref></contrib><contrib contrib-type="author"><name><surname>Beauduin</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="aff17"><sup>q</sup></xref></contrib><contrib contrib-type="author"><name><surname>Eymard</surname><given-names>Jean-Christophe</given-names></name><xref ref-type="aff" rid="aff18"><sup>r</sup></xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Anne-Laure</given-names></name><xref ref-type="aff" rid="aff19"><sup>s</sup></xref></contrib><contrib contrib-type="author"><name><surname>Roché</surname><given-names>Henri</given-names></name><xref ref-type="aff" rid="aff20"><sup>t</sup></xref></contrib><on-behalf-of>on behalf of the UNICANCER Breast Group</on-behalf-of><aff id="aff1"><sup>a</sup>Medical Oncology, Centre Georges-François Leclerc, Dijon, France;</aff><aff id="aff2"><sup>b</sup>Statistical Department, Institut Curie, Paris, France;</aff><aff id="aff3"><sup>c</sup>Medical Oncology, Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Nantes, France;</aff><aff id="aff4"><sup>d</sup>Medical Oncology, Institut Gustave Roussy, Villejuif, France;</aff><aff id="aff5"><sup>e</sup>Medical Oncology, Cliniques Universitaires Saint Luc, Bruxelles, Belgium;</aff><aff id="aff6"><sup>f</sup>Pathology Department, Centre Jean Perrin, Clermont-Ferrand, France;</aff><aff id="aff7"><sup>g</sup>Medical Oncology, Institut Sainte-Catherine, Avignon, France;</aff><aff id="aff8"><sup>h</sup>Medical Oncology, Centre François Baclesse, Caen, France;</aff><aff id="aff9"><sup>i</sup>Medical Oncology, Centre Val d'Aurelle, Montpellier, France;</aff><aff id="aff10"><sup>j</sup>Medical Oncology, Grand Hôpital Charleroi, Charleroi, Belgium;</aff><aff id="aff11"><sup>k</sup>Medical Oncology, Centre Hospitalier Fleyriat, Bourg-en-Bresse, France;</aff><aff id="aff12"><sup>l</sup>Medical Oncology, Centre Medico-Chirurgical les Ormeaux, Le Havre, France;</aff><aff id="aff13"><sup>m</sup>Medical Oncology, Centre Paul Strauss, Strasbourg, France;</aff><aff id="aff14"><sup>n</sup>Medical Oncology, Centre Hospitalo-Universitaire Sart-Tilman, Liège, Belgium;</aff><aff id="aff15"><sup>o</sup>Medical Oncology, Centre Hospitalier, Colmar, France;</aff><aff id="aff16"><sup>p</sup>Medical Oncology, Centre Henri Becquerel, Rouen, France;</aff><aff id="aff17"><sup>q</sup>Medical Oncology, Hôpital Jolimont, Haine-Saint-Paul, Belgium;</aff><aff id="aff18"><sup>r</sup>Medical Oncology, Institut Jean Godinot, Reims, France;</aff><aff id="aff19"><sup>s</sup>Unicancer, Fédération Nationale des Centres de Lutte Contre le Cancer, Paris, France;</aff><aff id="aff20"><sup>t</sup>Medical Oncology, Institut Claudius Regaud, Toulouse, France</aff></contrib-group><author-notes><corresp>Correspondence: Bruno Coudert, M.D., Centre Georges-François Leclerc, 1 Rue du Professeur Marion, 21000 Dijon, France. Telephone:
<phone>+33 (0)3 80 73 77 20</phone>; Fax:
<fax>+33 (0)3 80 73 77 12</fax>; e-mail: <email>bcoudert@cgfl.fr</email></corresp><fn fn-type="conflict"><p><bold>Disclosures: Bruno Coudert:</bold> Sanofi-Aventis, Roche (C/A); Lilly, AstraZeneca, Amgen (H); <bold>Mario Campone:</bold> Novartis (C/A). The other authors indicated no financial relationships.</p></fn></author-notes><pub-date pub-type="ppub"><month>7</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>18</day><month>5</month><year>2012</year></pub-date><volume>17</volume><issue>7</issue><fpage>900</fpage><lpage>909</lpage><history><date date-type="received"><day>15</day><month>12</month><year>2011</year></date><date date-type="accepted"><day>26</day><month>4</month><year>2012</year></date></history><permissions><copyright-statement>©AlphaMed Press</copyright-statement><copyright-year>2012</copyright-year></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="onc00712000900.pdf"></self-uri><abstract abstract-type="precis"><p>The initial report from the PACS01 trial demonstrated a benefit at 5 years for disease-free survival and overall survival rates with the sequential administration of docetaxel after fluorouracil, epirubicin, and cyclophosphamide for patients with node-positive, operable breast cancer. This article evaluates the impact of this regimen at 8 years.</p></abstract><abstract><sec><title>Purpose.</title><p>The initial report from the Programme Action Concertée Sein (PACS) PACS01 trial demonstrated a benefit at 5 years for disease-free survival (DFS) and overall survival (OS) rates with the sequential administration of docetaxel after FEC100 (fluorouracil 500 mg/m<sup>2</sup>, epirubicin 100 mg/m<sup>2</sup>, and cyclophosphamide 500 mg/m<sup>2</sup>) for patients with node-positive, operable breast cancer. We evaluate here the impact of this regimen at 8 years.</p></sec><sec><title>Patients and Methods.</title><p>Between June 1997 and March 2000, a total of 1,999 patients (age <65) with localized, resectable, non-pretreated, unilateral breast cancer were randomly assigned to receive either standard FEC100 for 6 cycles or 3 cycles of FEC100 followed by 3 cycles of 100 mg/m<sup>2</sup> docetaxel (FEC-D), both given every 21 days. Radiotherapy was mandatory after conservative surgery and tamoxifen was given for 5 years to hormone receptor (HR)-positive patients. Five-year DFS was the trial's main endpoint. Updated 8-year survival data are presented.</p></sec><sec><title>Results.</title><p>With a median follow-up of 92.8 months, 639 patients experienced at least one event. A total number of 383 deaths were registered. Eight-year DFS rates were 65.8% with FEC alone and 70.2% with FEC-D. OS rates at 8 years were 78% with FEC alone and 83.2% with FEC-D. Cox regression analysis adjusted for age and number of positive nodes showed a 15% reduction in the relative risk of relapse and a 25% reduction in the relative risk of death in favor of FEC-D. Significant relative risk reductions were observed in the HR-positive, HER2-positive, and Ki67 ≥20% subpopulations.</p></sec><sec><title>Conclusion.</title><p>Benefits for DFS and OS rates with the sequential FEC-D regimen are fully confirmed at 8 years.</p></sec></abstract><kwd-group><kwd>Breast cancer</kwd><kwd>Adjuvant treatment</kwd><kwd>Epirubicin</kwd><kwd>Docetaxel</kwd><kwd>Sequential treatment</kwd><kwd>Randomized trial</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000193 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000193 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/France
|area= LeHavreV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:3399644
|texte= Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:22610153" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LeHavreV1
| This area was generated with Dilib version V0.6.25. |  |